Ontilyv
·
- Prescription status not stated
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Opicapone
- Made by
- Bial Portela & Companhia S.A.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Ontilyv is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
FranceNo exact match for this strength and form
Details
| Made by | Bial Portela & Companhia S.A. |
|---|---|
| Active substance | Opicapone |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Classification | N04,N04BX04 · Pain, sleep, mood, epilepsy and the brain |
| Authorised on | 2022-02-21 |
| Last updated by the regulator | 2025-03-28 |
| EMA product number | EMEA/H/C/005782 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.